

Kessler Foundation Presents Data on Ekso(TM) at World Congress of Biomechanics

Another Step Highlighting Robotic Exoskeleton Technology in Rehabilitation

RICHMOND, Calif., July 22, 2014 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (OTCQB:EKSO), a robotic exoskeleton company, announced today that Kessler Foundation, a global leader in rehabilitation research, has presented preliminary data at World Congress of Biomechanics held in Boston, MA, July 5-10, showing that spinal cord injury (SCI) motor incomplete and complete users were able to actively increase step swing time, stride length and hip extension after walking with an Ekso™ robotic exoskeleton. Most notably, muscle activation per gait cycle increased with training and became more similar to able-bodied walking.

In an additional study, Kessler Foundation also reports on work focused on mathematically simulating human and exoskeleton interactions. The model will be useful in understanding the results of their on-going studies of intensive exoskeleton training. Kessler Foundation has been using Ekso Bionics' exoskeleton for clinical research in patients with spinal cord injury since October 2011 and recently acquired a second device to study utility and efficacy specifically for stroke survivors.

"We are seeing that robotics in rehabilitation are having an increasingly positive impact on patient outcomes, and research such as this is key to furthering such progress," said Rodger DeRose, president and chief executive officer of Kessler Foundation. "Exploring robotic exoskeletons is an exciting new avenue for our mobility researchers."

Ekso Bionics Chief Executive Officer Nathan Harding added, "It is very interesting to see that muscle activity increased in a patient with a complete spinal cord injury as they got more training. They will need more data, but this is a very intriguing result."

Ekso Bionics designs, develops, and commercializes exoskeletons, or wearable robots, which have a variety of applications in the medical, military, industrial, and consumer markets. Exoskeletons are ready-to-wear, battery-powered robots that are strapped over the user's clothing, enabling individuals to achieve mobility, strength, and endurance not otherwise possible. Ekso Bionics' lead product, Ekso™, is a wearable bionics suit that enables individuals with any amount of lower extremity weakness to stand up and walk over ground. Ekso is forging a new frontier in rehabilitation for people living with the consequences of stroke, spinal cord injury and other neurological conditions affecting gait.

About Kessler Foundation

Kessler Foundation, a major nonprofit organization in the field of disability, is a global leader

in rehabilitation research that seeks to improve cognition, mobility and long-term outcomes, including employment, for people with neurological disabilities caused by diseases and injuries of the brain and spinal cord. Kessler Foundation leads the nation in funding innovative programs that expand opportunities for employment for people with disabilities. For more information, visit KesslerFoundation.org.

About Ekso Bionics

Since 2005, Ekso Bionics has been pioneering the field of robotic exoskeletons, or wearable robots, to augment human strength, endurance and mobility. The company's first commercially available product called Ekso has helped thousands of people living with paralysis take millions of steps not otherwise possible. By designing and creating some of the most forward-thinking and innovative solutions for people looking to augment human capabilities, Ekso Bionics is helping people rethink current physical limitations and achieve the remarkable.

Ekso Bionics is headquartered in Richmond, CA and is listed on the OTC QB under the symbol EKSO. To learn more about Ekso Bionics please visit us at www.eksobionics.com

Facebook: www.facebook.com/eksobionics

Twitter: [@eksobionics](https://twitter.com/eksobionics)

YouTube: <https://www.youtube.com/user/EksoBionics/>

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain adequate financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and

the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC at <http://www.sec.gov>. The Company does not undertake to update these forward-looking statements.

CONTACT: Media Contact:

Heidi Darling, Marketing Manager
Phone: 415.302.4777
hdarling@eksobionics.com

Investor Contact:

Lauren Glaser, Vice President
Phone: 646.378.2972
lglaser@troutgroup.com

Source: Ekso Bionics